336 related articles for article (PubMed ID: 2409211)
1. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.
Kinoshita T; Medof ME; Silber R; Nussenzweig V
J Exp Med; 1985 Jul; 162(1):75-92. PubMed ID: 2409211
[TBL] [Abstract][Full Text] [Related]
2. [Paroxysmal nocturnal hemoglobinuria (PNH) deficiency of major complement-regulatory membrane proteins on erythrocytes].
Ninomiya H; Kobayashi T; Abe T
Rinsho Ketsueki; 1991 Jun; 32(6):612-7. PubMed ID: 1716325
[TBL] [Abstract][Full Text] [Related]
3. Decay-accelerating factor is present on paroxysmal nocturnal hemoglobinuria erythroid progenitors and lost during erythropoiesis in vitro.
Moore JG; Frank MM; Müller-Eberhard HJ; Young NS
J Exp Med; 1985 Oct; 162(4):1182-92. PubMed ID: 2413153
[TBL] [Abstract][Full Text] [Related]
4. Structural and functional differences between decay-accelerating factor and red cell acetylcholinesterase.
Sugarman J; Devine DV; Rosse WF
Blood; 1986 Sep; 68(3):680-4. PubMed ID: 2427138
[TBL] [Abstract][Full Text] [Related]
5. Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria.
Zalman LS; Wood LM; Frank MM; Müller-Eberhard HJ
J Exp Med; 1987 Feb; 165(2):572-7. PubMed ID: 2434597
[TBL] [Abstract][Full Text] [Related]
6. Deficiency of glycosyl-phosphatidylinositol anchored proteins on paroxysmal nocturnal haemoglobinuria (PNH) neutrophils and monocytes: heterogeneous deficiency of decay-accelerating factor (DAF) and CD16 on PNH neutrophils.
Kawakami Z; Ninomiya H; Tomiyama J; Abe T
Br J Haematol; 1990 Apr; 74(4):508-13. PubMed ID: 1693286
[TBL] [Abstract][Full Text] [Related]
7. Erythrocyte membrane protein deficiencies in paroxysmal nocturnal hemoglobinuria.
Schultz DR
Am J Med; 1989 Sep; 87(3N):22N-29N. PubMed ID: 2484793
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
Wilcox LA; Ezzell JL; Bernshaw NJ; Parker CJ
Blood; 1991 Aug; 78(3):820-9. PubMed ID: 1713516
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
Medof ME; Kinoshita T; Silber R; Nussenzweig V
Proc Natl Acad Sci U S A; 1985 May; 82(9):2980-4. PubMed ID: 2581259
[TBL] [Abstract][Full Text] [Related]
10. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
Davitz MA; Low MG; Nussenzweig V
J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
[TBL] [Abstract][Full Text] [Related]
11. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
Nicholson-Weller A; March JP; Rosenfeld SI; Austen KF
Proc Natl Acad Sci U S A; 1983 Aug; 80(16):5066-70. PubMed ID: 6576376
[TBL] [Abstract][Full Text] [Related]
12. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5430-4. PubMed ID: 6225118
[TBL] [Abstract][Full Text] [Related]
13. Expression of decay-accelerating factor and CD59 in lymphocyte subsets of healthy individuals and paroxysmal nocturnal hemoglobinuria patients.
Nagakura S; Nakakuma H; Horikawa K; Hidaka M; Kagimoto T; Kawakita M; Tomita M; Takatsuki K
Am J Hematol; 1993 May; 43(1):14-8. PubMed ID: 7686331
[TBL] [Abstract][Full Text] [Related]
14. Different distribution of decay-accelerating factor on hematopoietic progenitors from normal individuals and patients with paroxysmal nocturnal hemoglobinuria.
Kanamaru A; Okuda K; Ueda E; Kitani T; Kinoshita T; Nagai K
Blood; 1988 Aug; 72(2):507-11. PubMed ID: 2456796
[TBL] [Abstract][Full Text] [Related]
15. Enhanced complement-susceptibility and dysfunction of lymphocytes in paroxysmal nocturnal haemoglobinuria (PNH).
Tomiyama J; Ninomiya H; Abe T
Br J Haematol; 1990 Dec; 76(4):540-4. PubMed ID: 1702310
[TBL] [Abstract][Full Text] [Related]
16. Decay-accelerating factor (DAF) on the blood cell membranes in patients with paroxysmal nocturnal haemoglobinuria (PNH): measurement by enzyme-linked immunosorbent assay (ELISA).
Ninomiya H; Abe T; Shichishima T; Terasawa T; Fujita T
Br J Haematol; 1988 May; 69(1):81-7. PubMed ID: 2454648
[TBL] [Abstract][Full Text] [Related]
17. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
Medof ME; Gottlieb A; Kinoshita T; Hall S; Silber R; Nussenzweig V; Rosse WF
J Clin Invest; 1987 Jul; 80(1):165-74. PubMed ID: 2439544
[TBL] [Abstract][Full Text] [Related]
18. A high m.w. form of decay-accelerating factor (DAF-2) exhibits size abnormalities in paroxysmal nocturnal hemoglobinuria erythrocytes.
Kinoshita T; Rosenfeld SI; Nussenzweig V
J Immunol; 1987 May; 138(9):2994-8. PubMed ID: 2437202
[TBL] [Abstract][Full Text] [Related]
19. Robust in vitro replication of Plasmodium falciparum in glycosyl-phosphatidylinositol-anchored membrane glycoprotein-deficient red blood cells.
Pattanapanyasat K; Walsh DS; Yongvanitchit K; Piyawatthanasakul N; Wanachiwanawin W; Webster HK
Am J Trop Med Hyg; 2003 Oct; 69(4):360-5. PubMed ID: 14640493
[TBL] [Abstract][Full Text] [Related]
20. Proteolytic elimination of decay-accelerating factor (DAF): lytic abnormality coincides with removal of DAF in papain-treated human erythrocytes.
Seya T; Inoue H; Okada M; Matsumoto M; Kitamura H; Kinoshita T; Akedo H
Mol Immunol; 1990 Jan; 27(1):69-78. PubMed ID: 1690349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
